Have a personal or library account? Click to login
Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies Cover

Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies

Tremor and Other Hyperkinetic Movements
Volume 12 (2022): Issue 1
By: Ali H. Abusrair,  Walaa Elsekaily and  Saeed Bohlega  
Open Access
|Sep 2022

References

  1. 1Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA – Journal of the American Medical Association. 2020; 323: 548–60. DOI: 10.1001/jama.2019.22360
    Back to article
  2. 2Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Movement Disorders. 2014; 29: 454–62. DOI: 10.1002/mds.25844
    Back to article
  3. 3Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience. 2017; 18: 435–50. DOI: 10.1038/nrn.2017.62
    Back to article
  4. 4Zach H, Dirkx M, Bloem BR, et al. The clinical evaluation of Parkinson’s tremor. Journal of Parkinson’s Disease. 2015; 5: 471–4. DOI: 10.3233/JPD-150650
    Back to article
  5. 5Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: The patient’s perspective. Movement Disorders. 2010; 25: 1646–51. DOI: 10.1002/mds.23135
    Back to article
  6. 6Kipfer S. Resting Tremor in Parkinson Disease. Archives of Neurology. 2011; 68: 1037. DOI: 10.1001/archneurol.2011.147
    Back to article
  7. 7Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson’s disease: A clinical and neuroimaging study. Brain. 2018; 141: 811–21. DOI: 10.1093/brain/awx376
    Back to article
  8. 8Gironell A, Pascual-Sedano B, Aracil I, et al. Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson’s Disease; 2018. DOI: 10.1155/2018/4327597
    Back to article
  9. 9van Rooden SM, Heiser WJ, Kok JN, et al. The identification of Parkinson’s disease subtypes using cluster analysis: A systematic review. Movement Disorders. 2010; 25: 969–78. DOI: 10.1002/mds.23116
    Back to article
  10. 10Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale. Movement Disorders. 2013; 28: 668–70. DOI: 10.1002/mds.25383
    Back to article
  11. 11Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013; 84(4): 409–415. DOI: 10.1136/jnnp-2012-303455
    Back to article
  12. 12Aleksovski D, Miljkovic D, Bravi D, et al. Disease progression in Parkinson subtypes: the PPMI dataset. Neurological Sciences. 2018; 39: 1971–6. DOI: 10.1007/s10072-018-3522-z
    Back to article
  13. 13Fishman PS. Paradoxical aspects of parkinsonian tremor. Movement Disorders. 2008; 23: 168–73. DOI: 10.1002/mds.21736
    Back to article
  14. 14Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA – Journal of the American Medical Association. 2014; 311: 1670–83. DOI: 10.1001/jama.2014.3654
    Back to article
  15. 15Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry. 2020; 91: 795–808. DOI: 10.1136/jnnp-2019-322338
    Back to article
  16. 16Rajput AH, Voll A, Rajput ML, et al. Course in parkinson disease subtypes: A 39-year clinicopathologic study. Neurology. 2009; 73: 206–12. DOI: 10.1212/WNL.0b013e3181ae7af1
    Back to article
  17. 17Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurology. 2014; 71: 499–504. DOI: 10.1001/jamaneurol.2013.6233
    Back to article
  18. 18Hallett M. Parkinson’s disease tremor: Pathophysiology. Parkinsonism and Related Disorders. 2012; 18: S85–6. DOI: 10.1016/S1353-8020(11)70027-X
    Back to article
  19. 19Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. Curr Opin Neurol. 2020; 33(4): 474–481. DOI: 10.1097/WCO.0000000000000829
    Back to article
  20. 20Hallett M. Tremor: pathophysiology. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S118–S122. DOI: 10.1016/S1353-8020(13)70029-4
    Back to article
  21. 21Helmich RC, Dirkx MF. Pathophysiology and Management of Parkinsonian Tremor. Seminars in Neurology. 2017; 37: 127–34. DOI: 10.1055/s-0037-1601558
    Back to article
  22. 22Helmich RC. The cerebral basis of Parkinsonian tremor: A network perspective. Movement Disorders. 2018; 33: 219–31. DOI: 10.1002/mds.27224
    Back to article
  23. 23Helmich RC, Hallett M, Deuschl G, et al. Cerebral causes and consequences of parkinsonian resting tremor: A tale of two circuits? Brain. 2012; 135: 3206–26. DOI: 10.1093/brain/aws023
    Back to article
  24. 24Dirkx MF, Bologna M. The pathophysiology of Parkinson’s disease tremor. Journal of the Neurological Sciences. 2022; 435: 120196. DOI: 10.1016/j.jns.2022.120196
    Back to article
  25. 25Timmermann L, Gross J, Dirks M, et al. The cerebral oscillatory network of parkinsonian resting tremor. Brain. 2003; 126: 199–212. DOI: 10.1093/brain/awg022
    Back to article
  26. 26Dirkx MF, den Ouden H, Aarts E, et al. The cerebral network of parkinson’s tremor: An effective connectivity fMRI study. Journal of Neuroscience. 2016; 36: 5362–72. DOI: 10.1523/JNEUROSCI.3634-15.2016
    Back to article
  27. 27Dirkx MF, den Ouden HEM, Aarts E, et al. Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus. Brain. 2017; 140: 721–34. DOI: 10.1093/brain/aww331
    Back to article
  28. 28Kremer NI, Pauwels RWJ, Pozzi NG, et al. Deep brain stimulation for tremor: Update on long-term outcomes, target considerations and future directions. Journal of Clinical Medicine. 2021; 10. DOI: 10.3390/jcm10163468
    Back to article
  29. 29Duval C, Daneault JF, Hutchison WD, et al. A brain network model explaining tremor in Parkinson’s disease. Neurobiology of Disease. 2016; 85: 49–59. DOI: 10.1016/j.nbd.2015.10.009
    Back to article
  30. 30Helmich RC, Janssen MJR, Oyen WJG, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Annals of Neurology. 2011; 69: 269–81. DOI: 10.1002/ana.22361
    Back to article
  31. 31Underwood CF, Parr-Brownlie LC. Primary motor cortex in Parkinson’s disease: Functional changes and opportunities for neurostimulation. Neurobiology of Disease. 2021; 147. DOI: 10.1016/j.nbd.2020.105159
    Back to article
  32. 32Burciu RG, Vaillancourt DE. Imaging of Motor Cortex Physiology in Parkinson’s Disease. Movement Disorders. 2018; 33: 1688–99. DOI: 10.1002/mds.102
    Back to article
  33. 33Ni Z, Pinto AD, Lang AE, et al. Involvement of the cerebellothalamocortical pathway in Parkinson disease. Annals of Neurology. 2010; 68: 816–24. DOI: 10.1002/ana.22221
    Back to article
  34. 34Lu MK, Chiou SM, Ziemann U, et al. Resetting tremor by single and paired transcranial magnetic stimulation in Parkinson’s disease and essential tremor. Clinical Neurophysiology. 2015; 126: 2330–6. DOI: 10.1016/j.clinph.2015.02.010
    Back to article
  35. 35Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Movement Disorders. 2012; 27: 8–30. DOI: 10.1002/mds.23795
    Back to article
  36. 36Lee JY, Lao-Kaim NP, Pasquini J, et al. Pallidal dopaminergic denervation and rest tremor in early Parkinson’s disease: PPMI cohort analysis. Parkinsonism and Related Disorders. 2018; 51: 101–4. DOI: 10.1016/j.parkreldis.2018.02.039
    Back to article
  37. 37Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol. 1991; 50(6): 743–755. DOI: 10.1097/00005072-199111000-00006
    Back to article
  38. 38den Dunnen WF. Neuropathological diagnostic considerations in hyperkinetic movement disorders. Front Neurol. 2013; 4: 7. Published 2013 Feb 14. DOI: 10.3389/fneur.2013.00007
    Back to article
  39. 39Isaias IU, Marotta G, Pezzoli G, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology. 2011; 11. DOI: 10.1186/1471-2377-11-88
    Back to article
  40. 40Zach H, Dirkx MF, Pasman JW, et al. Cognitive Stress Reduces the Effect of Levodopa on Parkinson’s Resting Tremor. CNS Neuroscience and Therapeutics. 2017; 23: 209–15. DOI: 10.1111/cns.12670
    Back to article
  41. 41Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015; 138: 2964–73. DOI: 10.1093/brain/awv215
    Back to article
  42. 42Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: An [123I] β-CIT SPECT study. Journal of Neural Transmission. 2008; 115: 721–9. DOI: 10.1007/s00702-007-0015-2
    Back to article
  43. 43Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. Npj Parkinson’s Disease. 2016; 2. DOI: 10.1038/npjparkd.2016.1
    Back to article
  44. 44Lenka A, Jankovic J. Tremor Syndromes: An Updated Review. Frontiers in Neurology. 2021; 12: 1–17. DOI: 10.3389/fneur.2021.684835
    Back to article
  45. 45Hess CW, Pullman SL. Tremor: Clinical phenomenology and assessment techniques. Tremor and Other Hyperkinetic Movements. 2012; 2: 1–15. DOI: 10.5334/tohm.115
    Back to article
  46. 46Dirkx MF, Zach H, Bloem BR, et al. The nature of postural tremor in Parkinson disease. Neurology. 2018; 90: e1095–102. DOI: 10.1212/WNL.0000000000005215
    Back to article
  47. 47de Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. The Lancet Neurology. 2020; 19: 452–61. DOI: 10.1016/S1474-4422(20)30036-3
    Back to article
  48. 48Balestrino R, Schapira AHV. Parkinson disease. European Journal of Neurology. 2020; 27: 27–42. DOI: 10.1111/ene.14108
    Back to article
  49. 49Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA – Journal of the American Medical Association. 2014; 311: 1670–83. DOI: 10.1001/jama.2014.3654
    Back to article
  50. 50Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice Guideline summary. Neurology. 2021; 97: 942–57. DOI: 10.1212/WNL.0000000000012868
    Back to article
  51. 51Fox SH, Lang AE. Levodopa-related motor complications—phenomenology. Mov Disord. 2008; 23(Suppl 3): S509–S514. DOI: 10.1002/mds.22021
    Back to article
  52. 52Nonnekes J, Timmer MHM, de Vries NM, et al. Unmasking levodopa resistance in Parkinson’s disease. Movement Disorders. 2016; 31: 1602–9. DOI: 10.1002/mds.26712
    Back to article
  53. 53Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain. 1992; 115(Pt 6): 1701–1725. DOI: 10.1093/brain/115.6.1701
    Back to article
  54. 54Lee JE, Sweet RD, McDowell FH. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med. 1971; 75(5): 703–708. DOI: 10.7326/0003-4819-75-5-703
    Back to article
  55. 55Heusinkveld LE, Hacker ML, Turchan M, et al. Impact of tremor on patients with early stage parkinson’s disease. Frontiers in Neurology. 2018; 9. DOI: 10.3389/fneur.2018.00628
    Back to article
  56. 56Zach H, Dirkx M, Pasman JW, et al. The patient’s perspective: The effect of levodopa on Parkinson symptoms. Parkinsonism and Related Disorders. 2017; 35: 48–54. DOI: 10.1016/j.parkreldis.2016.11.015
    Back to article
  57. 57Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol. 1986; 43(2): 126–127. DOI: 10.1001/archneur.1986.00520020020009
    Back to article
  58. 58Imbach LL, Sommerauer M, Leuenberger K, et al. Dopamine-responsive pattern in tremor patients. Parkinsonism Relat Disord. 2014; 20(11): 1283–1286. DOI: 10.1016/j.parkreldis.2014.09.007
    Back to article
  59. 59Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020; 95(11): e1461–e1470. DOI: 10.1212/WNL.0000000000010316
    Back to article
  60. 60Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson’s disease. NPJ Parkinsons Dis. 2022; 8(1): 56. Published 2022 May 11. DOI: 10.1038/s41531-022-00321-y
    Back to article
  61. 61Gupta HV, Lyons KE, Wachter N, et al. Long Term Response to Levodopa in Parkinson’s Disease. J Parkinsons Dis. 2019; 9(3): 525–529. DOI: 10.3233/JPD-191633
    Back to article
  62. 62Caligiuri MP, Lohr JB. Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis. Clin Neuropharmacol. 1993; 16(3): 244–250. DOI: 10.1097/00002826-199306000-00008
    Back to article
  63. 63Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002; 72(6): 713–720. DOI: 10.1136/jnnp.72.6.713
    Back to article
  64. 64Elble RJ. Tremor and dopamine agonists. Neurology. 2002; 58(4 Suppl 1): S57–S62. DOI: 10.1212/WNL.58.suppl_1.S57
    Back to article
  65. 65Frei K, Truong DD. Medications used to treat tremors. J Neurol Sci. 2022; 435: 120194. DOI: 10.1016/j.jns.2022.120194
    Back to article
  66. 66Navan P, Findley LJ, Jeffs JA, et al. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s disease. Mov Disord. 2003; 18(2): 176–180. DOI: 10.1002/mds.10320
    Back to article
  67. 67Nigro S, Bordier C, Cerasa A, et al. Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson’s disease. Parkinsonism Relat Disord. 2019; 67: 14–20. DOI: 10.1016/j.parkreldis.2019.09.006
    Back to article
  68. 68Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother. 1995; 49(4): 197–209. DOI: 10.1016/0753-3322(96)82620-5
    Back to article
  69. 69Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019; 33: 905–18. DOI: 10.1007/s40263-019-00661-z
    Back to article
  70. 70Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 1990; 53: 1004–7. DOI: 10.1136/jnnp.53.11.1004
    Back to article
  71. 71Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018; 91: e189–201. DOI: 10.1212/WNL.0000000000005816
    Back to article
  72. 72Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [published correction appears in Arch Neurol.2005 Mar; 62(3): 430]. Arch Neurol. 2004; 61(7): 1044–1053. DOI: 10.1001/archneur.61.7.1044
    Back to article
  73. 73Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000; 342(20): 1484–1491. DOI: 10.1056/NEJM200005183422004
    Back to article
  74. 74Marras C, Chaudhuri KR, Titova N, et al. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics, 2020; 17: 1366–77. DOI: 10.1007/s13311-020-00894-7
    Back to article
  75. 75Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database of Systematic Reviews. 2002; 2010. DOI: 10.1002/14651858.CD003735
    Back to article
  76. 76Saeedi Y, Ghadimi M, Rohani M, et al. Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinson’s disease. Clinical Neurology and Neurosurgery. 2021; 202: 106480. DOI: 10.1016/j.clineuro.2021.106480
    Back to article
  77. 77van Hilten JJ, Ramaker CC, Stowe R, et al. Bromocriptine versus levodopa in early Parkinson’s disease. Cochrane Database Syst Rev. 2007; 2007(4): CD002258. Published 2007 Oct 17. DOI: 10.1002/14651858.CD002258.pub2
    Back to article
  78. 78Krishna R, Ali M, Moustafa AA. Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson’s disease. Frontiers in Aging Neuroscience. 2014; 6: 1–9. DOI: 10.3389/fnagi.2014.00180
    Back to article
  79. 79Lew MF. Rasagiline treatment effects on parkinsonian tremor. International Journal of Neuroscience. 2013; 123: 859–65. DOI: 10.3109/00207454.2013.812085
    Back to article
  80. 80Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol. 2011; 18(12): 1373–1378. DOI: 10.1111/j.1468-1331.2011.03512.x
    Back to article
  81. 81Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999; 340(10): 757–763. DOI: 10.1056/NEJM199903113401003
    Back to article
  82. 82Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Movement Disorders Clinical Practice. 2016; 3: 116–24. DOI: 10.1002/mdc3.12266
    Back to article
  83. 83Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: A retrospective analysis of a large multicentered clinical experience. Movement Disorders. 1998; 13: 377–82. DOI: 10.1002/mds.870130302
    Back to article
  84. 84Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010; 33(1): 14–16. DOI: 10.1097/WNF.0b013e3181c47168
    Back to article
  85. 85Crosby NJ, Deane K, Clarke CE. Beta-blocker therapy for tremor in Parkinson’s disease. Cochrane Database of Systematic Reviews. 2003; 2010. DOI: 10.1002/14651858.CD003361
    Back to article
  86. 86Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013; 73: 1405–15. DOI: 10.1007/s40265-013-0105-4
    Back to article
  87. 87Marjama-Lyons J, Koller W. Tremor-predominant Parkinson’s disease. Approaches to treatment. Drugs Aging. 2000; 16(4): 273–278. DOI: 10.2165/00002512-200016040-00003
    Back to article
  88. 88Bullock A, Kaul I, Li S, et al. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. Journal of the Neurological Sciences. 2021; 421: 117277. DOI: 10.1016/j.jns.2020.117277
    Back to article
  89. 89Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacological Reviews. 2017; 69: 200–35. DOI: 10.1124/pr.116.012658
    Back to article
  90. 90Kreisler A, Bouchain B, Defebvre L, et al. Treatment with Botulinum Neurotoxin Improves Activities of Daily Living and Quality of Life in Patients with Upper Limb Tremor. Tremor Other Hyperkinet Mov (NY). 2019; 9: 10.7916/tohm.v0.640. Published 2019 Jul 26. DOI: 10.5334/tohm.458
    Back to article
  91. 91Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021; 13. DOI: 10.3390/toxins13010042
    Back to article
  92. 92Niemann N, Jankovic J. Botulinum toxin for the treatment of hand tremor. Toxins (Basel). 2018; 10: 1–10. DOI: 10.3390/toxins10070299
    Back to article
  93. 93Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord. 1994; 9(6): 601–609. DOI: 10.1002/mds.870090604
    Back to article
  94. 94Mittal SO, Pandey S. Botulinum toxin for the treatment of tremor. Journal of the Neurological Sciences. 2022; 435: 120203. DOI: 10.1016/j.jns.2022.120203
    Back to article
  95. 95Mittal SO, Jog M, Lee J, et al. Novel botulinum toxin injection protocols for parkinson tremor and essential tremor – the yale technique and sensor-based kinematics procedure for safe and effective treatment. Tremor and Other Hyperkinetic Movements. 2020; 10: 1–8. DOI: 10.5334/tohm.582
    Back to article
  96. 96Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56: 1523–8. DOI: 10.1212/WNL.56.11.1523
    Back to article
  97. 97Mittal SO, Machado D, Richardson D, et al. Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach. Mayo Clinic Proceedings. 2017; 92: 1359–67. DOI: 10.1016/j.mayocp.2017.06.010
    Back to article
  98. 98Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS ONE. 2017; 12: 1–19. DOI: 10.1371/journal.pone.0178670
    Back to article
  99. 99Okun MS. Deep-brain stimulation – Entering the era of human neural-network modulation. New England Journal of Medicine. 2014; 371: 1369–73. DOI: 10.1056/NEJMp1408779
    Back to article
  100. 100Voges J, Waerzeggers Y, Maarouf M, et al. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery—experiences from a single centre. J Neurol Neurosurg Psychiatry. 2006; 77(7): 868–872. DOI: 10.1136/jnnp.2005.081232
    Back to article
  101. 101Hilker R, Benecke R, Deuschl G, et al. Tiefe Hirnstimulation bei idiopathischem Parkinson-Syndrom. Empfehlungen der Deutschen Arbeitsgemeinschaft Tiefe Hirnstimulation [Deep brain stimulation for Parkinson’s disease. Consensus recommendations of the German Deep Brain Stimulation Association]. Nervenarzt. 2009; 80(6): 646–655. DOI: 10.1007/s00115-009-2695-3
    Back to article
  102. 102Larson PS. Deep brain stimulation for movement disorders. Neurotherapeutics. 2014; 11(3): 465–474. DOI: 10.1007/s13311-014-0274-1
    Back to article
  103. 103Uc EY, Follett KA. Deep brain stimulation in movement disorders. Semin Neurol. 2007; 27(2): 170–182. DOI: 10.1055/s-2007-971175
    Back to article
  104. 104Siddiqui MS, Haq IU, Okun MS. Deep brain stimulation in movement disorders. Continuum (Minneap Minn). 2010; 16(1 Movement Disorders): 110–130. DOI: 10.1212/01.CON.0000348903.94715.b4
    Back to article
  105. 105Defer GL, Widner H, Marié RM, et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson’s disease (CAPSIT-PD). Movement Disorders. 1999; 14: 572–84. DOI: 10.1002/1531-8257(199907)14:4<;572::AID-MDS1005>3.0.CO;2-C
    Back to article
  106. 106Munhoz RP, Picillo M, Fox SH, et al. Eligibility Criteria for Deep Brain Stimulation in Parkinson’s Disease, Tremor, and Dystonia. Can J Neurol Sci. 2016; 43(4): 462–471. DOI: 10.1017/cjn.2016.35
    Back to article
  107. 107Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. Journal of Neurology. 2021; 268: 3135–43. DOI: 10.1007/s00415-020-09810-7
    Back to article
  108. 108Hirsch EC, Mouatt A, Faucheux B, et al. Dopamine, tremor, and Parkinson’s disease. Lancet. 1992; 340(8811): 125–126. DOI: 10.1016/0140-6736(92)90457-E
    Back to article
  109. 109Zheng Z, Yin Z, Zhang B, et al. Levodopa Challenge Test Predicts STN-DBS Outcomes in Various Parkinson’s Disease Motor Subtypes: A More Accurate Judgment. Neural Plasticity; 2021. DOI: 10.1155/2021/4762027
    Back to article
  110. 110Lin W, Shi D, Wang D, et al. Can Levodopa Challenge Testing Predict the Effect of Deep Brain Stimulation? One-Year Outcomes in a Chinese Cohort. Frontiers in Aging Neuroscience. 2021; 13: 1–7. DOI: 10.3389/fnagi.2021.764308
    Back to article
  111. 111Sandoe C, Krishna V, Basha D, et al. Predictors of deep brain stimulation outcome in tremor patients. Brain Stimulation. 2018; 11: 592–9. DOI: 10.1016/j.brs.2017.12.014
    Back to article
  112. 112Karas PJ, Mikell CB, Christian E, et al. Deep brain stimulation: a mechanistic and clinical update. Neurosurg Focus. 2013; 35(5): E1. DOI: 10.3171/2013.9.FOCUS13383
    Back to article
  113. 113Hwang JH, Paek SH, Jeon BS. Deep brain stimulation: mechanism, surgical procedure, and clinical applications. J Korean Med Assoc. 2013; 56(8): 695–701. DOI: 10.5124/jkma.2013.56.8.695
    Back to article
  114. 114Ashkan K, Rogers P, Bergman H, et al. Insights into the mechanisms of deep brain stimulation. Nat Rev Neurol. 2017; 13(9): 548–554. DOI: 10.1038/nrneurol.2017.105
    Back to article
  115. 115Herrington TM, Cheng JJ, Eskandar EN. Mechanisms of deep brain stimulation. Journal of Neurophysiology. 2016; 115: 19–38. DOI: 10.1152/jn.00281.2015
    Back to article
  116. 116Chiken S, Nambu A. Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption? Neuroscientist. 2016; 22: 313–22. DOI: 10.1177/1073858415581986
    Back to article
  117. 117Mure H, Hirano S, Tang CC, et al. Parkinson’s disease tremor-related metabolic network: Characterization, progression, and treatment effects. Neuroimage. 2011; 54: 1244–53. DOI: 10.1016/j.neuroimage.2010.09.028
    Back to article
  118. 118Peng S, Dhawan V, Eidelberg D, et al. Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders. Bioelectronic Medicine. 2021; 7. DOI: 10.1186/s42234-021-00065-9
    Back to article
  119. 119Little S, Beudel M, Zrinzo L, et al. Bilateral adaptive deep brain stimulation is effective in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2016; 87: 717–21. DOI: 10.1136/jnnp-2015-310972
    Back to article
  120. 120Alberts JL, Hass CJ, Vitek JL, et al. Are two leads always better than one: An emerging case for unilateral subthalamic deep brain stimulation in Parkinson’s disease. Experimental Neurology. 2008; 214: 1–5. DOI: 10.1016/j.expneurol.2008.07.019
    Back to article
  121. 121Mao Z, Ling Z, Pan L, et al. Comparison of efficacy of deep brain stimulation of different targets in Parkinson’s disease: A network meta-analysis. Frontiers in Aging Neuroscience. 2019; 10: 1–8. DOI: 10.3389/fnagi.2019.00023
    Back to article
  122. 122Groiss SJ, Wojtecki L, Sudmeyer M, et al. Deep brain stimulation in Parkinson-s disease. Therapeutic Advances in Neurological Disorders. 2009; 2: 379–91. DOI: 10.1177/1756285609339382
    Back to article
  123. 123Honey CR, Hamani C, Kalia SK, et al. Deep Brain Stimulation Target Selection for Parkinson’s Disease. Canadian Journal of Neurological Sciences. 2017; 44: 3–8. DOI: 10.1017/cjn.2016.22
    Back to article
  124. 124Wong JK, Viswanathan VT, Nozile-Firth KS, et al. STN Versus GPi Deep Brain Stimulation for Action and Rest Tremor in Parkinson’s Disease. Front Hum Neurosci. 2020; 14: 578615. Published 2020 Oct 23. DOI: 10.3389/fnhum.2020.578615
    Back to article
  125. 125Katlowitz K, Ko M, Mogilner AY, et al. Effect of deep brain simulation on arm, leg, and chin tremor in Parkinson disease [published online ahead of print, 2018 Dec 7]. J Neurosurg. 2018; 1–6. DOI: 10.3171/2018.7.JNS18784
    Back to article
  126. 126Lin Z, Zhang X, Wang L, et al. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson’s Disease. Frontiers in Human Neuroscience. 2021; 15: 1–10. DOI: 10.3389/fnhum.2021.604433
    Back to article
  127. 127Lyons KE, Koller WC, Wilkinson SB, et al. Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor. Journal of Neurology Neurosurgery and Psychiatry. 2001; 71: 682–4. DOI: 10.1136/jnnp.71.5.682
    Back to article
  128. 128Hartmann CJ, Fliegen S, Groiss SJ, et al. An update on best practice of deep brain stimulation in Parkinson’s disease. Therapeutic Advances in Neurological Disorders. 2019; 12: 1–20. DOI: 10.1177/1756286419838096
    Back to article
  129. 129Azghadi A, Rajagopal MM, Atkinson KA, et al. Tremor on medication. 2022; 136: 1364–70. DOI: 10.3171/2021.4.JNS21502
    Back to article
  130. 130Hitti FL, Ramayya AG, McShane BJ, et al. Long-term outcomes following deep brain stimulation for Parkinson’s disease [published online ahead of print, 2019 Jan 18]. J Neurosurg. 2019; 1–6. DOI: 10.3171/2018.8.JNS182081
    Back to article
  131. 131Fukaya C, Watanabe M, Kobayashi K, et al. Predictive factors for long-term outcome of subthalamic nucleus deep brain stimulation for parkinson’s disease. Neurologia Medico-Chirurgica. 2017; 57: 166–71. DOI: 10.2176/nmc.oa.2016-0114
    Back to article
  132. 132Bove F, Mulas D, Cavallieri F, et al. Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease. Neurology. 2021; 97: E254–62. DOI: 10.1212/WNL.0000000000012246
    Back to article
  133. 133Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019; 15: 234–42. DOI: 10.1038/s41582-019-0145-9
    Back to article
  134. 134Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Movement Disorders. 2010; 25: 578–86. DOI: 10.1002/mds.22735
    Back to article
  135. 135Volkmann J, Albanese A, Kulisevsky J, et al. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson’s disease. Movement Disorders. 2009; 24: 1154–61. DOI: 10.1002/mds.22496
    Back to article
  136. 136Hariz MI, Krack P, Alesch F, et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: A 6 year follow-up. Journal of Neurology, Neurosurgery and Psychiatry. 2008; 79: 694–9. DOI: 10.1136/jnnp.2007.118653
    Back to article
  137. 137Pahwa R, Lyons KE, Wilkinson SB, et al. Long-term evaluation of deep brain stimulation of the thalamus. Journal of Neurosurgery. 2006; 104: 506–12. DOI: 10.3171/jns.2006.104.4.506
    Back to article
  138. 138Ahmed H, Field W, Hayes MT, et al. Evolution of Movement Disorders Surgery Leading to Contemporary Focused Ultrasound Therapy for Tremor. Magnetic Resonance Imaging Clinics of North America. 2015; 23: 515–22. DOI: 10.1016/j.mric.2015.05.008
    Back to article
  139. 139Walters H, Shah BB. Focused Ultrasound and Other Lesioning Therapies in Movement Disorders. Curr Neurol Neurosci Rep. 2019; 19: 66. DOI: 10.1007/s11910-019-0975-2
    Back to article
  140. 140Ohye C, Higuchi Y, Shibazaki T, et al. Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurgery. 2012; 70(3): 526–536. DOI: 10.1227/NEU.0b013e3182350893
    Back to article
  141. 141Lim SY, Hodaie M, Fallis M, et al. Gamma knife thalamotomy for disabling tremor: A blinded evaluation. Archives of Neurology. 2010; 67: 584–8. DOI: 10.1001/archneurol.2010.69
    Back to article
  142. 142Berg D, Corvol J. European Academy of Neurology/Movement Disorder Society- European Section Guideline on the Treatment of Parkinson’s Disease: I. Invasive Therapies. 2022; 37: 1360–74. DOI: 10.1002/mds.29066
    Back to article
  143. 143Fishman PS, Frenkel V. Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease. Neurotherapeutics. 2017; 14: 393–404. DOI: 10.1007/s13311-017-0515-1
    Back to article
  144. 144Lennon JC, Hassan I. Magnetic resonance-guided focused ultrasound for Parkinson’s disease since ExAblate, 2016–2019: a systematic review. Neurol Sci. 2021; 42: 553–63. DOI: 10.1007/s10072-020-05020-1
    Back to article
  145. 145Martínez-Fernández R, Máñez-Miró JU, Rodríguez-Rojas R, et al. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease. New England Journal of Medicine. 2020; 383: 2501–13. DOI: 10.1056/NEJMoa2016311
    Back to article
  146. 146Krishna V, Sammartino F, Cosgrove R, et al. Predictors of Outcomes After Focused Ultrasound Thalamotomy. Neurosurgery. 2020; 87: 229–37. DOI: 10.1093/neuros/nyz417
    Back to article
  147. 147Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017; 74: 1412–8. DOI: 10.1001/jamaneurol.2017.3098
    Back to article
  148. 148Gallay MN, Moser D, Magara AE, et al. Bilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson’s Disease With 1-Year Follow-Up. Front Neurol. 2021; 12: 601153. DOI: 10.3389/fneur.2021.601153
    Back to article
  149. 149Martinez-Fernandez R, Mahendran S, Pineda-Pardo JA, et al. Bilateral staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of essential tremor: a case series study. J Neurol Neurosurg Psychiatry. 2021; 92: 927–31. DOI: 10.1136/jnnp-2020-325278
    Back to article
  150. 150Xu Y, He Q, Wang M, et al. Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson’s disease: a systematic review. Neurosurgical Review. 2021; 44: 115–27. DOI: 10.1007/s10143-019-01216-y
    Back to article
  151. 151Ohye C, Shibazaki T. Treatment of functional disorders with gamma knife thalamotomy. Prog Neurol Surg. 2009; 22: 170–181. DOI: 10.1159/000163416
    Back to article
  152. 152Ohye C, Shibazaki T, Ishihara J, et al. Evaluation of gamma thalamotomy for parkinsonian and other tremors: survival of neurons adjacent to the thalamic lesion after gamma thalamotomy. J Neurosurg. 2000; 93(Suppl 3): 120–127. DOI: 10.3171/jns.2000.93.supplement_3.0120
    Back to article
  153. 153Higuchi Y, Matsuda S, Serizawa T. Gamma knife radiosurgery in movement disorders: Indications and limitations. Movement Disorders. 2017; 32: 28–35. DOI: 10.1002/mds.26625
    Back to article
  154. 154Young RF, Jacques S, Mark R, et al. Gamma knife thalamotomy for treatment of tremor: long-term results. J Neurosurg. 2000; 93(Suppl 3): 128–135. DOI: 10.3171/jns.2000.93.supplement_3.0128
    Back to article
  155. 155Cho KR, Kim HR, Im YS, et al. Outcome of gamma knife thalamotomy in patients with an intractable tremor. J Korean Neurosurg Soc. 2015; 57: 192–6. DOI: 10.3340/jkns.2015.57.3.192
    Back to article
  156. 156Doshi PK. Radiofrequency Lesioning for Movement and Psychiatric Disorders-Experience of 107 Cases. Frontiers in Human Neuroscience. 2021; 15: 673848. DOI: 10.3389/fnhum.2021.673848
    Back to article
  157. 157Horisawa S, Fukui A, Nonaka T, et al. Radiofrequency Ablation for Movement Disorders: Risk Factors for Intracerebral Hemorrhage, a Retrospective Analysis. Oper Neurosurg (Hagerstown). 2021; 21(3): 143–149. DOI: 10.1093/ons/opab169
    Back to article
  158. 158Artusi CA, Balestrino R, Imbalzano G, et al. Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors. Parkinsonism and Related Disorders. 2020; 76: 98–103. DOI: 10.1016/j.parkreldis.2019.10.004
    Back to article
  159. 159Wang L, Li J, Chen J. Levodopa-Carbidopa Intestinal Gel in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology. 2018; 9. DOI: 10.3389/fneur.2018.00620
    Back to article
  160. 160Fernandez HH, Robieson WZ, Chatamra K, et al. Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease. Npj Parkinson’s Disease. 2016; 2: 1–6. DOI: 10.1038/npjparkd.2016.15
    Back to article
  161. 161Chalah MA, Lefaucheur JP, Ayache SS. Non-invasive central and peripheral stimulation: New hope for essential tremor? Frontiers in Neuroscience. 2015; 9: 1–11. DOI: 10.3389/fnins.2015.00440
    Back to article
  162. 162Wu AD, Fregni F, Simon DK, et al. Noninvasive Brain Stimulation for Parkinson’s Disease and Dystonia. Neurotherapeutics. 2008; 5: 345–61. DOI: 10.1016/j.nurt.2008.02.002
    Back to article
  163. 163Madrid J, Benninger DH. Non-invasive brain stimulation for Parkinson’s disease: Clinical evidence, latest concepts and future goals: A systematic review. Journal of Neuroscience Methods. 2021; 347: 108957. DOI: 10.1016/j.jneumeth.2020.108957
    Back to article
  164. 164Meng L, Jin M, Zhu X, et al. Peripherical Electrical Stimulation for Parkinsonian Tremor: A Systematic Review. Frontiers in Aging Neuroscience. 2022; 14: 1–11. DOI: 10.3389/fnagi.2022.795454
    Back to article
  165. 165Pascual-Valdunciel A, Hoo GW, Avrillon S, et al. Peripheral electrical stimulation to reduce pathological tremor: a review. J Neuroeng Rehabil. 2021; 18(1): 33. Published 2021 Feb 15. DOI: 10.1186/s12984-021-00811-9
    Back to article
  166. 166Oliveira de Carvalho A, Filho ASS, Murillo-Rodriguez E. Physical Exercise For Parkinson’s Disease: Clinical And Experimental Evidence. Clin Pract Epidemiol Ment Health. 2018; 14: 89–98. Published 2018 Mar 30. DOI: 10.2174/1745017901814010089
    Back to article
  167. 167Tsukita K, Sakamaki-Tsukita H, Takahashi R. Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease. Neurology. 2022; 98(8): e859–e871. DOI: 10.1212/WNL.0000000000013218
    Back to article
  168. 168Zhang D, Poignet P, Widjaja F, et al. Neural oscillator based control for pathological tremor suppression via functional electrical stimulation. Control Engineering Practice. 2011; 19: 74–88. DOI: 10.1016/j.conengprac.2010.08.009
    Back to article
  169. 169Bhidayasiri R, Maytharakcheep S, Phumphid S, et al. Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology. Journal of the Neurological Sciences. 2022; 435: 120197. DOI: 10.1016/j.jns.2022.120197
    Back to article
DOI: https://doi.org/10.5334/tohm.712 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Jun 22, 2022
Accepted on: Aug 26, 2022
Published on: Sep 13, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Parkinson’s Disease,
Tremor,
Levodopa-resistant,
DBS

© 2022 Ali H. Abusrair, Walaa Elsekaily, Saeed Bohlega, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 12 (2022): Issue 1Next article